Novo Nordisk A/S (NVO)
Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 15.2148
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 2041427598963.2886
- FreeCF/Share 16.8361
- PFCF 27.3123
- PE 20.1487
- Debt/Assets 0.2427
- DivYield 0.0221
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Shareholders that Lost Money on Novo Nordisk A/S(NVO) Should Contact Levi & Korsinsky about Pending Class Action - NVO
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=131029&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Read More
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130955&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Novo Nordisk A/S
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 02, 2022 and December 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Novo Nordisk A/S to Contact the Firm Today!
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. Adding 5m GLP-1 patients at slightly lower prices or 21m at LLY price levels both lead to 20%+ upside in the stock. Both diabetes and obesity are blue ocean markets, composed of low GLP-1 usage.
Read More
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35.4% year-on-year despite competition from Mounjaro. In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations.
Read More
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130721&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130745&wire=1 or contact Joseph E. Levi, Esq.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Novo Nordisk A/S to Contact the Firm Today!
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit – NVO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130383&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130424&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – NV
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Shareholders that lost money on Novo Nordisk A/S (NVO) should contact Levi & Korsinsky about pending Class Action - NVO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130301&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
Read More
ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Investors who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130291&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024.
Read More
Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130113&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline.
Read More
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
Published: February 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. So what: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130069&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema.
Read More
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=130038&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 02, 2022 and December 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Published: February 17, 2025 by: MarketBeat
Sentiment: Neutral
Shares of weight loss and diabetes medication maker Novo Nordisk NYSE: NVO have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close.
Read More
NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Mr. Lars Fruergaard Jorgensen
- Employees 77406